JNJ
Johnson & Johnson · Healthcare · Drug Manufacturers - General
すべての保有状況データ:追跡対象13Fマネージャーのみ、普通株ポジション、報告期間 Q2 2024
| 四半期 | 保有者 | Δ | 株数 | 報告済み評価額 | 新規 | 解消銘柄 |
|---|---|---|---|---|---|---|
| Q2 2026 | 183 | +1 | 1.45B | $367.13B | +5 | −3 |
| Q1 2026 | 184 | 0 | 1.43B | $348.29B | +4 | −5 |
| Q4 2025 | 183 | 0 | 1.52B | $314.40B | +2 | −1 |
| Q3 2025 | 28 | 0 | 887.20M | $164.46B | — | −1 |
| Q2 2025 | 26 | +1 | 740.96M | $113.15B | +1 | — |
| Q1 2025 | 22 | -1 | 281.15M | $46.60B | — | −1 |
| Q4 2024 | 23 | +3 | 290.64M | $42.01B | +3 | — |
| Q3 2024 | 19 | -2 | 157.55M | $25.50B | — | −2 |
| Q2 2024 | 21 | — | 161.11M | $23.53B | — | — |
| # | 運用会社 | 株数 | Δ株式数 | 時価 | そのウェイト | 保有中 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (パッシブ) | 55.10M | — | $8.03B | 0.7% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (パッシブ) | 55.10M | — | $8.03B | 0.7% | n/c | 1 | SEC ↗ |
| 3 | Norges Bank ✦ (パッシブ) | 29.09M | — | $4.25B | 0.6% | n/c | 1 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 24.91M | — | $3.64B | 0.4% | n/c | 1 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 24.91M | — | $3.64B | 0.4% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 24.85M | — | $3.63B | 0.7% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 24.85M | — | $3.63B | 0.7% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 24.85M | — | $3.63B | 0.7% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 24.85M | — | $3.63B | 0.7% | n/c | 1 | SEC ↗ |
| 10 | Wellington Management ✦ | 24.85M | — | $3.63B | 0.7% | n/c | 1 | SEC ↗ |
| 11 | Wellington Management ✦ | 24.85M | — | $3.63B | 0.7% | n/c | 1 | SEC ↗ |
| 12 | Wellington Management ✦ | 24.85M | — | $3.63B | 0.7% | n/c | 1 | SEC ↗ |
| 13 | Fisher Asset Management ✦ | 7.01M | — | $1.02B | 0.4% | n/c | 1 | SEC ↗ |
| 14 | Marshall Wace ✦ | 3.88M | — | $567.83M | 0.8% | n/c | 1 | SEC ↗ |
| 15 | Marshall Wace ✦ | 3.88M | — | $567.83M | 0.8% | n/c | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 3.35M | — | $489.18M | 0.8% | n/c | 1 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 3.35M | — | $489.18M | 0.8% | n/c | 1 | SEC ↗ |
| 18 | AQR Capital Management ✦ | 3.35M | — | $489.18M | 0.8% | n/c | 1 | SEC ↗ |
| 19 | AQR Capital Management ✦ | 3.35M | — | $489.18M | 0.8% | n/c | 1 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 3.35M | — | $489.18M | 0.8% | n/c | 1 | SEC ↗ |
| 21 | Bridgewater Associates ✦ | 3.20M | — | $468.34M | 2.4% | n/c | 1 | SEC ↗ |
| 22 | Renaissance Technologies ✦ | 1.53M | — | $223.58M | 0.4% | n/c | 1 | SEC ↗ |
| 23 | Citadel Advisors ✦ | 1.46M | — | $212.68M | 0.2% | n/c | 1 | SEC ↗ |
| 24 | Citadel Advisors ✦ | 1.46M | — | $212.68M | 0.2% | n/c | 1 | SEC ↗ |
| 25 | D. E. Shaw & Co. ✦ | 1.16M | — | $170.12M | 0.3% | n/c | 1 | SEC ↗ |
| 26 | D. E. Shaw & Co. ✦ | 1.16M | — | $170.12M | 0.3% | n/c | 1 | SEC ↗ |
| 27 | Tweedy, Browne ✦ | 1.13M | — | $165.23M | 7.6% | n/c | 1 | SEC ↗ |
| 28 | Millennium Management ✦ | 1.08M | — | $157.41M | 0.1% | n/c | 1 | SEC ↗ |
| 29 | Adage Capital Partners ✦ | 852.52K | — | $124.60M | 0.2% | n/c | 1 | SEC ↗ |
| 30 | Arrowstreet Capital ✦ | 828.12K | — | $121.04M | 0.1% | n/c | 1 | SEC ↗ |
| 31 | Two Sigma Investments ✦ | 649.75K | — | $94.97M | 0.2% | n/c | 1 | SEC ↗ |
| 32 | Markel Group ✦ | 610.80K | — | $89.27M | 0.9% | n/c | 1 | SEC ↗ |
| 33 | Markel Group ✦ | 610.80K | — | $89.27M | 0.9% | n/c | 1 | SEC ↗ |
| 34 | Gotham Asset Management ✦ | 218.02K | — | $31.87M | 0.4% | n/c | 1 | SEC ↗ |
| 35 | GAMCO Investors ✦ | 98.36K | — | $14.38M | 0.2% | n/c | 1 | SEC ↗ |
| 36 | Fairfax Financial ✦ | 73.40K | — | $10.72M | 0.9% | n/c | 1 | SEC ↗ |
| 37 | Dodge & Cox ✦ | 21.10K | — | $3.08M | 0.0% | n/c | 1 | SEC ↗ |
「当該ウェイト」= そのマネージャーの報告済み13F株式評価額に占めるポジションの割合(確信度の指標)。✦ = キュレーション済みマネージャー。
新規買い手
| 今四半期は新規追跡買い手がいません。 |
ポジション解消済み
| 今四半期は追跡されたエグジットがありません。 |
市場全体のコンテキスト: 全13Fファイラー対象(SEC構造化データ、 Q1 2026): 1 保有者, 136.10K 株式数, $33,268 報告済み. これは上記の追跡対象ユニバースの数値とは異なる、より古い期間のものであり、両者が混在することはありません。
この有価証券の追跡対象保有者が最も頻繁に保有する他の銘柄 — ファンダメンタルな関係ではなく、共同保有件数に基づきます。
市場内買い付け (P)
カバレッジ期間内にインサイダーによる市場内買い付けはありません。
市場内売却 (S)
Officer · 15.00K 株 · $3.95M
Officer, Director · 20.98K 株 · $5.50M
Officer, Director · 102.31K 株 · $26.70M
株式付与、権利行使および税務目的の株式差し引きは、買いや売りとして集計しません。 方法論
The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson's drug to treat a…
Reuters